A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which we estimate 1.1 million are annual surgical candidates. We have pioneered and patented the Lapiplasty® 3D Bunion Correction® System—a combination of instruments, implants and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion, and helping patients get back to their active lifestyles.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 213M | 213M | 209M | 187M | 142M | 94M |
| Net Income | -59M | -59M | -56M | -50M | -43M | -21M |
| EPS | $-0.93 | $-0.93 | $-0.90 | $-0.81 | $-0.77 | $-0.43 |
| Free Cash Flow | -29M | -29M | -49M | -46M | -45M | -20M |
| ROIC | -28.9% | -38.2% | -33.5% | -25.9% | -37.8% | -16.9% |
| Gross Margin | 79.8% | 79.8% | 80.4% | 81.2% | 82.0% | 81.1% |
| Debt/Equity | 0.82 | 0.82 | 0.61 | 0.50 | 1.13 | 0.33 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -54M | -54M | -56M | -51M | -35M | -17M |
| Operating Margin | -25.5% | -25.5% | -26.6% | -27.5% | -24.6% | -17.5% |
| ROE | -67.6% | -58.9% | -49.4% | -35.9% | -70.7% | -22.3% |
| Shares Outstanding | 63M | 63M | 62M | 61M | 56M | 48M |
| Metric | 2020 | 2021 | 2022 | 2023 | |||
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 57M | 94M | 142M | 187M | 209M | 213M | 213M |
| Gross Margin | 78.3% | 81.1% | 82.0% | 81.2% | 80.4% | 79.8% | 79.8% |
| R&D | 5.8M | 10M | 14M | 15M | 21M | 20M | 20M |
| SG&A | 6.5M | 18M | 33M | 47M | 56M | 63M | 63M |
| EBIT | 855K | -17M | -35M | -51M | -56M | -54M | -54M |
| Op. Margin | 1.5% | -17.5% | -24.6% | -27.5% | -26.6% | -25.5% | -25.5% |
| Net Income | -4.3M | -21M | -43M | -50M | -56M | -59M | -59M |
| Net Margin | -7.5% | -22.0% | -30.2% | -26.5% | -26.6% | -27.7% | -27.7% |
| Non-Recurring | 0 | 347K | 300K | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||
| ROIC | 1.6% | -16.9% | -37.8% | -25.9% | -33.5% | -38.2% | -28.9% |
| ROE | -555.2% | -22.3% | -70.7% | -35.9% | -49.4% | -58.9% | -67.6% |
| ROA | -10.3% | -14.7% | -26.9% | -19.7% | -25.7% | -28.9% | -31.0% |
| Cash Flow | |||||||
| Op. Cash Flow | -4.5M | -17M | -31M | -35M | -37M | -16M | -16M |
| Free Cash Flow | -5.6M | -20M | -45M | -46M | -49M | -29M | -29M |
| Owner Earnings | -6.6M | -21M | -41M | -57M | -76M | -60M | -60M |
| CapEx | 1.1M | 2.7M | 15M | 11M | 12M | 14M | 14M |
| Maint. CapEx | 1.2M | 685K | 2.1M | 5.4M | 8.4M | 11M | 11M |
| Growth CapEx | 0 | 2.0M | 13M | 6.1M | 3.2M | 2.9M | 2.9M |
| D&A | 1.2M | 685K | 2.1M | 5.4M | 8.4M | 11M | 11M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 919K | 3.4M | 8.1M | 17M | 31M | 34M | 34M |
| Debt Repayment | 179K | 1.8M | 0 | 0 | 0 | 1.2M | 1.2M |
| Balance Sheet | |||||||
| Net Debt | -3.4M | -75M | -13M | -54M | -6.4M | 23M | 61M |
| Cash & Equiv. | 18M | 106M | 19M | 13M | 11M | 11M | 11M |
| Long-Term Debt | 29M | 29M | 53M | 53M | 53M | 56M | 56M |
| Debt/Equity | 42.22 | 0.33 | 1.13 | 0.50 | 0.61 | 0.82 | 0.82 |
| Interest Coverage | 0.3 | -4.1 | -7.9 | -10.0 | -10.6 | -10.2 | -10.2 |
| Equity | 776K | 93M | 61M | 138M | 113M | 87M | 87M |
| Total Assets | 42M | 141M | 159M | 252M | 217M | 191M | 191M |
| Total Liabilities | 41M | 48M | 98M | 114M | 104M | 103M | 103M |
| Intangibles | N/A | N/A | 0 | 9.0M | 8.1M | 7.1M | 7.1M |
| Retained Earnings | -21M | -42M | -85M | -134M | -190M | -249M | -249M |
| Working Capital | 29M | 120M | 103M | 153M | 126M | 101M | 101M |
| Current Assets | 41M | 138M | 133M | 198M | 161M | 132M | 132M |
| Current Liabilities | 12M | 18M | 30M | 45M | 35M | 31M | 31M |
| Per Share Data | |||||||
| EPS | -0.12 | -0.43 | -0.77 | -0.81 | -0.90 | -0.93 | -0.93 |
| Owner EPS | -0.18 | -0.44 | -0.74 | -0.94 | -1.23 | -0.95 | -0.95 |
| Book Value | 0.02 | 1.93 | 1.09 | 2.26 | 1.82 | 1.38 | 1.38 |
| Cash Flow/Share | -0.13 | -0.36 | -0.55 | -0.57 | -0.60 | -0.25 | -0.76 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 35.9M | 48.3M | 55.6M | 61.1M | 61.9M | 63.4M | 63.4M |
| Valuation | |||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | -2.3 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 8.9 | 20.9 | 5.7 | 3.8 | 1.8 | 1.5 |
| Price/Sales | N/A | 13.5 | 7.7 | 6.4 | 2.5 | 2.0 | 0.6 |
| FCF Yield | N/A | -2.4% | -3.6% | -5.8% | -11.3% | -19.2% | -21.8% |
| Market Cap | N/A | 826M | 1.3B | 788M | 432M | 154M | 135M |
| Avg. Price | N/A | 26.33 | 19.62 | 19.45 | 8.61 | 6.61 | 2.13 |
| Year-End Price | N/A | 17.12 | 22.80 | 12.88 | 6.98 | 2.42 | 2.13 |
TREACE MEDICAL CONCEPTS, INC. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 80.9%.
TREACE MEDICAL CONCEPTS, INC. (TMCI) has a 5-year average return on invested capital (ROIC) of -30.5%. This is below average and may indicate limited pricing power.
TREACE MEDICAL CONCEPTS, INC. (TMCI) has a market capitalization of $135M. It is classified as a small-cap stock.
TREACE MEDICAL CONCEPTS, INC. (TMCI) does not currently pay a regular dividend.
TREACE MEDICAL CONCEPTS, INC. (TMCI) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
TREACE MEDICAL CONCEPTS, INC. (TMCI) reported annual revenue of $213 million in its most recent fiscal year, based on SEC EDGAR filings.
TREACE MEDICAL CONCEPTS, INC. (TMCI) has a net profit margin of -27.7%. The company is currently unprofitable.
TREACE MEDICAL CONCEPTS, INC. (TMCI) generated $-29 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
TREACE MEDICAL CONCEPTS, INC. (TMCI) has a debt-to-equity ratio of 0.82. This indicates moderate leverage.
TREACE MEDICAL CONCEPTS, INC. (TMCI) reported earnings per share (EPS) of $-0.93 in its most recent fiscal year.
TREACE MEDICAL CONCEPTS, INC. (TMCI) has a return on equity (ROE) of -58.9%. A negative ROE may indicate losses or negative equity.
TREACE MEDICAL CONCEPTS, INC. (TMCI) has a 5-year average gross margin of 80.9%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 6 years of financial data for TREACE MEDICAL CONCEPTS, INC. (TMCI), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
TREACE MEDICAL CONCEPTS, INC. (TMCI) has a book value per share of $1.38, based on its most recent annual SEC filing.